The UAE Corporate Tax regime has moved transfer pricing firmly onto the governance agenda. The arm's length principle applies to transactions with Related Parties and Connected Persons, while prescribed taxpayers must maintain a Master File and Local File. Yet the more consequential question is not whether the documents exist. It is whether the economic outcome they defend is credible when tested against how the business actually operates.
That distinction matters because substance is not a separate compliance test to be completed once a year. It is the operating foundation of the transfer pricing position. A policy can be technically sophisticated and still be vulnerable if key decisions are made elsewhere, risks are not genuinely controlled by the entity said to bear them, or the evidence trail was assembled only after the year-end result was known.
The strategic shift: from documentation to coherence
In practice, the most defensible groups have coherence across four layers: legal form, operational conduct, financial outcomes and contemporaneous evidence. Weakness in any one layer can undermine the others. An agreement may allocate market risk to a UAE distributor, for example, but that allocation becomes difficult to sustain if pricing, customer strategy and inventory decisions are directed outside the UAE and the local entity has neither authority nor capacity to manage the downside.
Strategic implication: transfer pricing should be designed alongside the operating model - not documented after the operating model has already produced the result.
This changes the role of the functions, assets and risks analysis. FAR should not read like a catalogue of activities. Its real purpose is to identify the economically significant decisions that drive value and volatility: who sets strategy, who can accept or mitigate risk, what information they use, and whether they have the financial capacity to bear the consequences. Those findings should then shape entity characterization, method selection and the level of return.
Substance risk tends to crystallize where the group's legal narrative is more ambitious than its operating reality. Four areas deserve particular attention:
A common response to substance risk is to accumulate more documents. That can create volume without proof. The better approach is to map each material transfer pricing assertion to the evidence generated by the underlying business process. If a UAE entity is said to control a risk, the file should show who reviewed the relevant information, what alternatives were considered, who approved the decision, and how the outcome was monitored.
Board minutes can help, but they are rarely decisive on their own. More persuasive evidence often sits in ordinary operating records: delegated authority, investment papers, pricing approvals, budgets, customer negotiations, credit decisions, service deliverables, system access and management reporting. The test is whether the evidence demonstrates capability and actual conduct - not simply presence or formal approval.
For boards, CFOs and tax leaders, the priority is to identify where profits depend on assumptions about substance and then test those assumptions before they become audit positions. A focused review should ask:
This is more effective than a broad annual refresh because it directs attention to the transactions and assumptions most likely to affect profit allocation. It also brings tax, finance, legal and business teams into the same control framework.
Substance cannot be owned by the tax function alone; it is created or weakened, by day-to-day commercial decisions.
UAE businesses should treat substance as an early-warning system for transfer pricing risk. Where operational reality has moved ahead of the policy, the right response may be to update agreements and documentation. In other cases, pricing, governance, decision rights or even the operating model may need to change. The answer should follow the facts, not the desired tax outcome.
The objective is not to manufacture substance or produce a larger file. It is to ensure that value creation, risk control and remuneration remain aligned as the business evolves. Groups that can demonstrate that alignment with clear, contemporaneous evidence will be better placed to defend their UAE transfer pricing outcomes - and to make faster, more informed decisions when the business changes.